Bayer stock jump 9% as stroke drug trial revives confidence in pipeline

Core Viewpoint - Bayer shares experienced a significant increase following positive late-stage clinical trial results for its experimental cardiovascular drug asundexian, marking a rare positive development for its pharmaceutical division, which has faced challenges and rising litigation costs [1] Group 1 - Bayer's stock rose over 9%, reaching €30.30, the highest level in over a week [1]